Last updated: October 2026

SPK-10001 is an investigational gene therapy program from Spark Therapeutics designed to reduce huntingtin expression.

Current status

It remains in early clinical development, where researchers are evaluating delivery, safety, and biological activity. This candidate is investigational and is not FDA approved. Timing, eligibility, safety, effectiveness, availability, and cost remain uncertain.

For the newest coverage across the HD treatment pipeline, visit What’s Happening in HD Treatment.